In the US, Sinemet (carbidopa/levodopa systemic) is a member of the drug class dopaminergic antiparkinsonism agents and is used to treat GTP-CH Deficiency, Neuroleptic Malignant Syndrome, Parkinson's Disease and Restless Legs Syndrome.
US matches:
- Sinemet
- Sinemet CR Sustained-Release Tablets
- Sinemet CR
UK matches:
- Sinemet 12.5mg/50mg, 10mg/100mg, 25mg/100mg and 25mg/250mg Tablets
- Sinemet CR and Half Sinemet CR
- Sinemet 12.5mg/50mg, 10mg/100mg, 25mg/100mg and 25mg/250mg Tablets (SPC)
- Sinemet CR and Half Sinemet CR (SPC)
Ingredient matches for Sinemet
Carbidopa is reported as an ingredient of Sinemet in the following countries:
- Argentina
- Australia
- Austria
- Brazil
- Bulgaria
- Canada
- Czech Republic
- Denmark
- Estonia
- Finland
- Greece
- Hong Kong
- Iceland
- Ireland
- Latvia
- Lithuania
- Luxembourg
- Malaysia
- Netherlands
- New Zealand
- Norway
- Oman
- Peru
- Philippines
- Poland
- Portugal
- Singapore
- South Africa
- Spain
- Sri Lanka
- Switzerland
- Taiwan
- Thailand
- Turkey
- United States
- Venezuela
Carbidopa monohydrate (a derivative of Carbidopa) is reported as an ingredient of Sinemet in the following countries:
- Belgium
- Croatia (Hrvatska)
- France
- Greece
- Hungary
- Ireland
- Italy
- Spain
- Sweden
- United Kingdom
Levodopa is reported as an ingredient of Sinemet in the following countries:
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Bulgaria
- Canada
- Croatia (Hrvatska)
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Greece
- Hong Kong
- Hungary
- Iceland
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malaysia
- Netherlands
- New Zealand
- Norway
- Oman
- Peru
- Philippines
- Poland
- Portugal
- Singapore
- South Africa
- Spain
- Sri Lanka
- Sweden
- Switzerland
- Taiwan
- Thailand
- Turkey
- United Kingdom
- United States
- Venezuela
International Drug Name Search
Glossary
SPC | Summary of Product Characteristics (UK) |
Click for further information on drug naming conventions and International Nonproprietary Names.